Everything below concerns glucagon receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Typically, synthetic oligonucleotides are single-stranded DNA or RNA molecules around 15–25 bases in length. Oligonucleotides find a variety of applications in molecular biology and medicine. They are most commonly used as antisense oligonucleotides, small interfering RNA, primers for DNA sequencing and amplification, probes for detecting complementary DNA or RNA via molecular hybridization, tools for the targeted introduction of mutations and restriction sites, and for the synthesis of artificial genes. An emerging application of Oligonucleotide synthesis is the re-creation of viruses from sequence alone — either harmless, such as Phi X 174, or dangerous such as the 1917 influenza virus or SARS-CoV-2.
=== Glioma and chemotherapy resistance === ITGA1 has been implicated in resistance to glioma treatment as well. The particular treatment it is resistant to is temozolomide (TMZ), which is the standard first-line chemotherapy agent used with radiotherapy and adjuvant treatment. There is an observed elevation of ITGA1 expression in TMZ-resistant glioma tissues when compared with a control group of TMZ-sensitive cell lines. Tumor cell survival is promoted by ITGA1 activating the PI3K/AKT pathway, subsequently increasing the anti-apoptotic Bcl-2 signaling and reducing apoptosis. A regulatory pathway involving hsa_circ_0110757 and hsa-miR-1298-5p controls ITGA1 expression in TMZ-resistant glioma. hsc_circ_0110757 functions as a competing endogenous RNA by sponging miR-1298-5p, which promotes ITGA1 expression and leads to increased PI3K/AKT activation as well as reduced apoptosis, and enhanced TMZ resistance. Disrupting this pathway restores the cell sensitivity to chemotherapy. This supports ITGA1 as a possible therapeutic target to overcome drug resistance in glioma.
Bringing Sarafem to market harmed Lilly's reputation in some quarters. The diagnostic category of PMDD was controversial since it was first proposed in 1987, and Lilly's role in retaining it in the appendix of the DSM-IV-TR, the discussions for which began in 1998, has been criticized. Lilly was accused of inventing a disease to make money, and for not innovating but rather just seeking ways to continue making money from existing drugs. It was also criticized by the FDA and groups concerned with women's health for marketing Sarafem too aggressively when it was first launched; the campaign included a television commercial featuring a harried woman at the grocery store who asks herself if she has PMDD.
Sources: en.wikipedia.org
To the east and north of the rebuilt central city are a stretch of old neighbourhoods (Danton, Saint-Vincent, Graville, Massillon, etc.) which were spared the bombings of World War II. The buildings, usually in brick, dated to the 19th and the first half of the 20th centuries. The shops are concentrated along several major roads in the Rond-Point neighbourhood. During the 1990s and 2000s, these neighborhoods have seen major redevelopments, particularly in the context of an OPAH: improvement of habitat by rehabilitation or reconstruction, creation of public facilities, and revitalization of business. At the end of the 20th century and beginning of the 21st century, the area around the railway station has undergone a major transformation. As the station is the gateway to the city with the main avenues intersecting here. New buildings have sprung up (University of Le Havre, the conservatory, headquarters of the SPB (Provident Society Bank), and of CMA CGM, Novotel, Matmut, new CCI) some of which were designed by renowned architects. The bus station, certified NF since 2005, has been refurbished. North of the station, another construction project in place of the dilapidated island of Turgot-Magellan will be opened in 2013, including 12,500 m2 (135,000 sq ft) of office space and an eight-storey hotel, complete with shops on the ground-floor.
The two substrates of this enzyme are L-lysine and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are (2S)-2,3,4,5-tetrahydropyridine-2-carboxylic acid (1), ammonia, reduced NADH, and a proton. The enzyme is highly specific for L-lysine as substrate, although S-(2-aminoethyl)-L-cysteine can act as a substrate, but more slowly.
=== Exoenzymes === Exoenzymes are enzymes secreted by microorganisms, such as bacteria and fungi, to function outside their cells. These enzymes are crucial for breaking down large molecules in the environment into smaller ones that the microorganisms can absorb (transport into their cells) and use for growth and energy. Several studies have demonstrated that the activity of extracellular enzymes in aquatic microbial ecology is of algal origin. These exoenzymes released from microalgae include alkaline phosphatases, chitinases, β-d-glucosidases, proteases etc. and can influence the growth of microorganisms, chemical signaling, and biogeochemical cycling in ecosystems. The study of these exoenzymes may help to optimize the nutrient supplement strategy in aquaculture. Nevertheless, only a few of the enzymes were isolated and purified. Selected prominent enzyme classes are highlighted in the cited literature.
Sources: en.wikipedia.org
== Adverse effects == Although generally well tolerated, the most common adverse reactions associated with ceftriaxone are changes in white blood cell counts, local reactions at site of administration, rash, and diarrhea. Incidence of adverse effects greater than 1%:
== National laws, regulations, and management == Laws governing aquaculture practices vary greatly by country and are often not closely regulated or easily traceable. In the United States, land-based and nearshore aquaculture is regulated at the federal and state levels; no national laws govern offshore aquaculture in U.S. exclusive economic zone waters. In June 2011, the Department of Commerce and National Oceanic and Atmospheric Administration released national aquaculture policies to address this issue and "to meet the growing demand for healthy seafood, to create jobs in coastal communities, and restore vital ecosystems." Large aquaculture facilities (i.e. those producing 20,000 pounds (9,100 kg) per year) which discharge wastewater are required to obtain permits pursuant to the Clean Water Act. Facilities that produce at least 100,000 pounds (45,000 kg) of fish, molluscs or crustaceans a year are subject to specific national discharge standards. Other permitted facilities are subject to effluent limitations that are developed on a case-by-case basis.
The Lord Ramage series by Dudley Pope takes place during the Napoleonic Wars. Jeanette Winterson's 1987 novel The Passion. Georgette Heyer's 1937 novel An Infamous Army recounts the fortunes of a family in the run-up to and during the course of, the Battle of Waterloo. Heyer's novel is noted for its meticulous research on the progress of the battle, combining her noted period romance writing with her detailed research into regency history. The Battle (French: La Bataille) is a historical novel by the French author Patrick Rambaud that was first published in 1997 and again in English in 2000. The book describes the 1809 Battle of Aspern-Essling between the French Empire under Napoleon and the Austrian Empire. The novel was awarded the Prix Goncourt and the Grand Prix du roman de l'Académie française for 1997. In Jasper Kent's novel Twelve, 1812 Russian Invasion serves as a base story for the book. In later books from The Danilov Quintet, this war is constantly mentioned. The Fighting Sail series by Alaric Bond portrays life and action aboard Royal Naval vessels during the Revolutionary and Napoleonic Wars. From the lower decks to the quarterdeck Bond's detailed settings are realistic. Narratives are told not just from a commissioned officer's point of view but include varied perspectives, including warranted officers, ordinary and able seamen, marines, supernumeraries, and women aboard presenting a broader, more complete picture of the Georgian Navy.
Medical acupuncture attempts to integrate reflexological concepts, the trigger point model, and anatomical insights (such as dermatome distribution) into acupuncture practice, and emphasizes a more formulaic approach to acupuncture point location. Cosmetic acupuncture is the use of acupuncture in an attempt to reduce wrinkles on the face. Bee venom acupuncture is a treatment approach of injecting purified, diluted bee venom into acupoints. Veterinary acupuncture is the use of acupuncture on domesticated animals.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.